Navigation path

Themes
Agriculture & food
Energy
Environment
ERA-NET
Health & life sciences
Human resources & mobility
Industrial research
Information society
Innovation
International cooperation
Nanotechnology
Pure sciences
Research infrastructures
Research policy
Science & business
Science in society
Security
SMEs
Social sciences and humanities
Space
Special Collections
Transport

Countries
Countries
  Argentina
  Australia
  Austria
  Belgium
  Brazil
  Bulgaria
  Canada
  Chile
  China
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Egypt
  Estonia
  Finland
  France
  Georgia
  Germany
  Ghana
  Greece
  Hungary
  Iceland
  India
  Ireland
  Israel
  Italy
  Japan
  Kazakhstan
  Kenya
  Korea
  Latvia
  Lithuania
  Luxembourg
  Malta
  Montenegro
  Morocco
  Namibia
  Netherlands
  Nigeria
  Norway
  Peru
  Poland
  Portugal
  Romania
  Russia
  Serbia
  Slovakia
  Slovenia
  South Africa
  Spain
  Sweden
  Switzerland
  Taiwan
  Tunisia
  Turkey
  Ukraine
  United Kingdom
  United States


   Success Stories

Last Update: 19-06-2013  
Related category(ies):
Health & life sciences

 

Countries involved in the project described in the article:
Austria  |  Germany  |  Spain
Add to PDF "basket"

Hope sparked by new vaccine for Alzheimer's

Brain research has made unprecedented progress over the years, with Europe at the forefront of scientific advances. But more can be done. This comes from Alzheimer's Disease International who issued their report on the Global Economic Impact of Dementia. They estimate that if dementia care were a country, it would be the world's 18th largest economy, ranking between Turkey and Indonesia.

Signaling an important breakthrough ©  Shutterstock

The European MIMOVAX project has high hopes of making a significant breakthrough in this important area of medical research. Alzheimer's Disease (AD) is a progressive, degenerative and irreversible brain disorder that causes intellectual impairment and disorientation. With no effective treatment, the MIMOVAX team has set out to develop a vaccination which can ensure safe and effective treatment, and ultimately halt progression of this crippling disease.

MIMOVAX is a 'Specific Targeted Research Project' (STREP) which targets truncated peptides Aß40/42 – derived from the Amyloid Precursor Protein (APP) – through active immunisation. The team focused on the use of immune reactions to fight known and less well-known beta amyloid (BA) proteins, which are thought to cause the disease.

The initial three-year project (extended to another 15 months to fulfil clinical objectives) was led by the Austrian company AFFiRiS AG. The consortium comprised three other industrial companies, two university institutes and a clinic, with a total of 20 scientists. The project received funding of EUR 4.3 million, of which EUR 2.4 came from the European Commission.

During the course of MIMOVAX, several AD vaccine candidates have been identified, which demonstrate the ability to reduce amyloid plaque load and alleviate the pathologic hallmarks of AD in the brain of animal models. In addition, according to the research team, a vaccination using AD vaccine candidates, improved spatial memory and learning in transgenic animals, thereby showing the potential for altering disease progression in these models. These experiments led to the identification of the AD03 vaccine as a candidate for clinical testing.

Dr Markus Mandler, the scientific coordinator at AFFiRiS AG explains: 'A clinical study using AD03 was conducted on 24 elderly patients with mild AD. Over the course of 12 months we studied the safety and tolerability of the vaccine. We then followed the patients up for a further 12 months to assess their behaviour. The results from these tests are currently being evaluated and we should see the final analysis in a few months.'

He adds: 'Once we see the full results we will decide whether to embark on further clinical testing, eventually leading to studies and data which can be presented to regulatory authorities for review and approval.'

Project details

  • Project acronym: MIMOVAX
  • Participants: Austria (Coordinator), Spain, Germany
  • Project FP6 37702
  • Total costs: €4 327 500
  • EU contribution: €2 370 155
  • Duration: October 2006 - December 2010

Convert article(s) to PDF

No article selected


loading


Search articles
To restrict search results to articles in the Information Centre, i.e. this site, use the search box at the top of the page to the right of the menu and then select "Information Centre" in the "Filter by" menu on the results page.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also

Project web site
Project information on CORDIS
Alzheimer's Disease International





  Top   Research Information Center